Achilles therapeutics reports third quarter 2023 financial results and recent highlights

– on track to dose 15-20 patients with higher dose cnet by year-end 2023 – – clinical and translational science data update from the ongoing phase i/iia trials in nsclc and melanoma expected in q1 2024 with additional data available in mid-2024 – – strong cash position of $140 million supports operations through 2025 –         london, nov. 13, 2023 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended september 30, 2023, and recent business highlights. “we are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology.
ACHL Ratings Summary
ACHL Quant Ranking